Potential Revenue

Potential Revenue model for ALVIZON™ for the GA Indication alone:

  • Number of people in target market: 8.5 – 17 million.
  • Conservatively assuming adoption by 5% of target market receiving 4 treatments per annum each: 1.7. – 3.4 million vials used annually for GA alone.

Potential annual revenue for ALVIZON™ is US$425m – US$850m for the GA Indication alone.

A conservative estimation of price per vial is US$250.

Why ALVIZON™?

The key clinical advantages of ALVIZON™ include:

  • Improved retinal anatomy and function.
  • Improved visual acuity.
  • No evidence of sustained increase in IOP or cataractogenisis.
  • Significant inhibition in rate of GA lesion spread.
  • No evidence of refractility.
  • Patents have been granted in over 30 countries for its use in Dry-AMD and GA.